A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

/by

Authors: Susan Short, Christopher Twelves, Lucy Brazil, Catherine McBain, et al
Clinicaltrials.gov, 11 August 2016
—
An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A). A randomisation phase to assess the safety of Sativex compared with placebo (Part B). Patient…

Read more